Journal of Cardiac Failure
Volume 15, Issue 10 , Pages 835-842 , December 2009

Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial

  • Peter Carson, MD

      Affiliations

    • Veterans Affairs Medical Center, Washington, DC
    • Corresponding Author InformationReprint requests: Peter Carson, MD, Veterans Affairs Medical Center, 50 Irving Street NW, Washington, DC 20422-0001. Tel: (202) 745-8109; Fax: (202) 745-8172.
    • ,
  • S. William Tam, PhD

      Affiliations

    • NitroMed, Inc., Lexington, MA
    • ,
  • Jalal K. Ghali, MD

      Affiliations

    • Wayne State University, Detroit, MI
    • ,
  • W. Tad Archambault, PhD

      Affiliations

    • Virtu Stat, Ltd, North Wales, PA
    • ,
  • Anne Taylor, MD, FACC

      Affiliations

    • Columbia University Medical Center, New York, NY
    • ,
  • Jay N. Cohn, MD, FACC

      Affiliations

    • University of Minnesota, Minneapolis, MN
    • ,
  • Virginia M. Braman

      Affiliations

    • NitroMed, Inc., Lexington, MA
    • ,
  • Manuel Worcel, MD

      Affiliations

    • NitroMed, Inc., Lexington, MA
    • ,
  • Inder S. Anand, MD, FACC, FRCP, DPHIL (OXON.)

      Affiliations

    • University of Minnesota, Minneapolis, MN
    • Veterans Affairs Medical Center, Minneapolis, MN

Received 6 January 2009 ,Revised 28 May 2009 ,Accepted 29 May 2009.

References 

  1. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490–498
  2. Carson P, Tognoni G, Cohn JN. Effect of Valsartan on hospitalization: results from ValHeFT. J Card Fail. 2003;9:164–171
  3. Rector TS, Francis GS, Cohn JN. Patients' self-assessment of their congestive heart failure. Part 1: patient perceived dysfunction and its poor correlation with maximal exercise tests. Heart Failure. 1987;192–196
  4. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure questionnaire. Heart Failure. 1987;198–209
  5. Rector TS, Johnson G, Dunkman WB, Daniels G, Farrell L, Henrick A, et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI71–VI77
  6. Gorkin L, Norvell NK, Rosen RC, Charles E, Schumaker SA, Melntyre KM, et al. for the SOLVD Investigators Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) trial quality-of-life substudy. Am J Cardiol. 1993;71:1069–1073
  7. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with heart failure questionnaire as a measure of therapeutic response to Enalapril or placebo. Am J Cardiol. 1993;71:1106–1107
  8. Rector TS, Tschumperlin LK, Kubo SH, Bank AJ, Francis GS, McDonald KM, et al. Use of the Living with Heart Failure questionnaire to ascertain patients' perspective on improvement in quality of life versus risk of drug-induced death. J Cardiac Failure. 1995;1:201–206
  9. Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, et al. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. Am J Cardiol. 1996;78:890–895
  10. Hulsmann M, Berger R, Sturm B, et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J. 2002;23:886–891
  11. Cowley AJ, Wiens BL, Segal R, Rich MW, Santanello NC, et al. Randomized comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy. Qual Life Res. 2000;9:377–384
  12. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295–1302
  13. Alla F, Briancon S, Guillemin F, et al. Self-rated quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. Eur J Heart Fail. 2002;4:337–343
  14. Lader E, Egan D, Hunsberger S, et al. The effect of digoxin on the quality of life in patients with heart failure. J Card Fail. 2003;9:4–12
  15. Rodriguez-Artalejo F, Guallar-Castillon P, Pascual CR, et al. Health-related quality of life as a predictor of hospital readmission and death among patients with heart failure. Arch Intern Med. 2005;165:1274–1279
  16. Majani G, Giardini A, Opasich C, et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. J Card Fail. 2005;11:253–259
  17. Tate CW, Robertson AD, Zolty R, et al. Quality of life and prognosis in heart failure: results of the beta-blocker evaluation of survival trial (BEST). J Card Fail. 2007;13:732–737
  18. Lewis EF, Lamas GA, Meara EO, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9:83–91
  19. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526–535
  20. Kubo SH, Schulman S, Starling RC, Jessup M, Wentworth D, Burkhoff D. Development and validation of a patient questionnaire to determine New York Heart Association classification. J Card Fail. 2004;10:228–235
  21. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, et al. The African-American Heart Failure Trial Investigators: combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057
  22. Franciosa JA, Taylor AL, Cohn JN, et al. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail. 2002;8:128–135
  23. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007;115:1747–1753
  24. Conard MW, Haddock K, Poston WSC, et al. Impact of obesity on the health status of heart failure patients. J Card Fail. 2006;12:700–706
  25. Masoudi FA, Rumsfeld JS, Havraned EP, et al. Age, functional capacity, and health-related quality of life in patients with heart failure. J Card Fail. 2004;10:368–373
  26. Rector TS, Anand IS, Cohn JN. Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life. J Card Fail. 2006;12:87–92
  27. Chin MH, Goldman L. Gender differences in 1-year survival and quality of life among patients admitted with congestive heart failure. Med Care. 1998;36:1033–1046
  28. Rumsfeld JS, Havranek E, Masoudi FA, et al. Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol. 2003;42:1811–1817
  29. Havranek EP, Spertus JA, Masoudi FA, et al. Predictors of the onset of depressive symptoms in patients with heart failure. J Am Coll Cardiol. 2004;44:2333–2338
  30. Luther SA, McCullough PA, Havranek EP, et al. The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Card Fail. 2005;11:414–421
  31. Best VA Coordinating Center; personal communication, 2007.
  32. Heidenreich PA, Spertus JA, Jones PG, et al. Health status identifies heart failure outpatients at risk for hospitalizations or death. J Am Coll Cardiol. 2006;47:752–756
  33. Soto GE, Jones P, Weintraub WS, et al. Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation. 2004;110:546–551
  34. Kosiborod M, Soto GE, Jones PG, et al. Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation. 2007;115:1975–1981
  35. Dorbe D, van Jaarsveld CH, deJongste MJ, et al. The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Safety. 2007;16:152–159

 All decisions for this manuscript were made by a guest editor.

 A-HeFT was funded by NitroMed, Inc, Lexington, MA. Authors are either consultants of NitroMed, Inc. (A.N.T., I.S.A., J.K.G., J.N.C., P.C., W.T.A.) or are/were employees of NitroMed (V.B., M.W., S.W.T.). Dr. Cohn has a royalty relationship with NitroMed based on his patents of the drug combination.

 Dr. Braman was an employee of NitroMed, Inc. from 2001-2008.

 Dr. Taylor has received research support and honoraria from NitroMed, Inc.

 Dr. Archambault served as a consultant to NitroMed, Inc.

 A-HeFT = African-American Heart Failure Trial BEST = Beta-Blocker Evaluation of Survival Trial CHARM = Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity.

PII: S1071-9164(09)00192-4

doi: 10.1016/j.cardfail.2009.05.016

Journal of Cardiac Failure
Volume 15, Issue 10 , Pages 835-842 , December 2009

Article Tools

* Image Usage & Resolution